Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 41.08
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 978939130820.0
- FreeCF/Share 10.0576
- PFCF 108.5214
- PE 53.0862
- Debt/Assets 0.3698
- DivYield 0.0055
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
Published: January 09, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Lilly's Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
Published: January 08, 2026 by: Reuters
Sentiment: Positive
Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Taltz alone.
Read More
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)
Published: January 08, 2026 by: Newsfile Corp
Sentiment: Neutral
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders …
Read More
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
Read More
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
Published: January 06, 2026 by: WSJ
Sentiment: Positive
The more-than-$1 billion deal could come imminently.
Read More
Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Eli Lilly, Nimbus Partner to Develop, License Oral Obesity Treatment
Published: January 06, 2026 by: WSJ
Sentiment: Positive
Eli Lilly and Nimbus Therapeutics have entered into a multiyear collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.
Read More
Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum
Published: January 06, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly (LLY) remains a Strong Buy, driven by robust GLP-1 demand and stellar execution, delivering a 34% total return since initial bullish coverage. LLY's Q3 results showed a 10% revenue and 19% EPS beat, with operating margin expanding from 40% to 48% YoY, and cash from operations surging to $8.8 billion. Flagship products Mounjaro and Zepbound posted 100%+ YoY revenue growth; late-stage pipeline assets like orforglipron and retatrutide reinforce LLY's GLP-1 leadership.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Read More
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?
Published: January 06, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent quarters thanks to its weight loss portfolio.
Read More
3 Reasons Why Lilly (LLY) Is a Great Growth Stock
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
Read More
3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.
Read More
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.
Read More
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Published: January 05, 2026 by: Market Watch
Sentiment: Positive
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Read More
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Read More
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Read More
In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s
Published: December 31, 2025 by: Barrons
Sentiment: Positive
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Read More
Eli Lilly's New Drug Data Sets Up a High-Stakes 2026
Published: December 26, 2025 by: MarketBeat
Sentiment: Positive
Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.
Read More
Focus: Lilly, Novo lock horns in India's obesity drug race
Published: December 23, 2025 by: Reuters
Sentiment: Neutral
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Graham: A.I. & Fed Top 2026 Themes, Top Picks in ANET, COHR & LLY
Published: December 19, 2025 by: Schwab Network
Sentiment: Positive
Andrew Graham says the next couple weeks will be hard to "separate the signal from the noise" in the A.I.-centric rebound due to low volume trading.
Read More
Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Published: December 19, 2025 by: 24/7 Wall Street
Sentiment: Positive
Eli Lilly ( NYSE:LLY ) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
3 Momentum Stocks That Could Continue Their Strong Run in 2026
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.
Read More
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
Published: December 17, 2025 by: Market Watch
Sentiment: Positive
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Read More
Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly
Published: December 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Very few investors can match Stanley Druckenmiller.
Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Published: December 16, 2025 by: CNBC
Sentiment: Positive
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000